Technical Analysis for APTO - Aptose Biosciences, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.38 | -0.08% | 0.00 |
Earnings due: Nov 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Fell Below 50 DMA | Bearish | -0.08% | |
20 DMA Support | Bullish | -0.08% | |
Bollinger Band Squeeze | Range Contraction | -0.08% | |
NR7 | Range Contraction | -0.08% |
Alert | Time |
---|---|
Possible NR7 | about 20 hours ago |
Possible Inside Day | about 20 hours ago |
20 DMA Support | about 23 hours ago |
60 Minute Opening Range Breakout | about 23 hours ago |
60 Minute Opening Range Breakdown | about 24 hours ago |
Get a Trading Assistant
- Earnings date: 11/07/2024
Aptose Biosciences, Inc. Description
Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Drugs Immunotherapy Oncology Acute Myeloid Leukemia Pancreatic Cancer Cancer Therapies Hematologic Malignancies Targeted Therapy Bacterial Infections Small Molecule Therapies Treatment Of Acute Myeloid Leukemia Preclinical Stage Product Phosphoinositide 3 Kinase Inhibitor Stage Products Bemcentinib Gemcitabine Preclinical Stage Products Treatment Of Pancreatic Cancer Drug Resistant Bacterial Infections
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.32 |
52 Week Low | 0.33 |
Average Volume | 601,105 |
200-Day Moving Average | 1.01 |
50-Day Moving Average | 0.38 |
20-Day Moving Average | 0.38 |
10-Day Moving Average | 0.39 |
Average True Range | 0.03 |
RSI (14) | 47.92 |
ADX | 18.67 |
+DI | 10.65 |
-DI | 13.07 |
Chandelier Exit (Long, 3 ATRs) | 0.33 |
Chandelier Exit (Short, 3 ATRs) | 0.42 |
Upper Bollinger Bands | 0.40 |
Lower Bollinger Band | 0.35 |
Percent B (%b) | 0.58 |
BandWidth | 13.61 |
MACD Line | 0.00 |
MACD Signal Line | -0.01 |
MACD Histogram | 0.0023 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.40 | ||||
Resistance 3 (R3) | 0.40 | 0.39 | 0.39 | ||
Resistance 2 (R2) | 0.39 | 0.38 | 0.39 | 0.39 | |
Resistance 1 (R1) | 0.38 | 0.38 | 0.39 | 0.39 | 0.39 |
Pivot Point | 0.38 | 0.38 | 0.38 | 0.38 | 0.38 |
Support 1 (S1) | 0.37 | 0.37 | 0.38 | 0.37 | 0.37 |
Support 2 (S2) | 0.37 | 0.37 | 0.37 | 0.37 | |
Support 3 (S3) | 0.36 | 0.37 | 0.37 | ||
Support 4 (S4) | 0.36 |